ABSTRACT. The origin of intact (78-kD) lactoferrin found in the urine of human milk-fed preterm infants was investigated using human milk containing proteins enriched with [13Cjle~cine and ['5N2]lysine or [2H4]lysine. Mothers of infants selected for the study were infused i.v. with [I3q leucine and ["N2]lysine or [2H4]lysine to label milk proteins. The labeled milk was collected from each mother, pooled, fortified with a lyophilized human milk fraction, and fed to her preterm infant by continuous orogastric infusion for a period of 48 h. Urine was collected from each infant for 96 h. Intact lactoferrin (78 kD) and DNAbinding lactoferrin fragments (51 and 39 kD) were purified from the urine by affinity chromatography on columns of immobilized single-stranded DNA-agarose. The concentration and isotopic enrichment of the intact lactoferrin and DNA-binding fragments were determined separately after their isolation by high-performance reverse-phase (phenyl) chromatography. Mass spectral analyses indicated that the isotopic enrichment of the purified urinary lactoferrin was 87 to 100% of that in the labeled human milk lactoferrin. Similar results were obtained for the isolated DNA-binding lactoferrin fragments. The ratios of isotopically labeled leucine to lysine in the purified milk lactoferrins and urinary lactoferrins were similar for each motherfinfant pair. Isotopically labeled lysine, added to the milk as free amino acid, was not incorporated into the purified urinary lactoferrin. These results demonstrate that undegraded (78-kD) lactoferrin of maternal origin is absorbed by the gut and excreted intact in the urine of preterm infants; nearly all of the urinary lactoferrin was of maternal origin. Lactofemn is a major constituent of human colostral milk and whey (I). This 78-kD secretory glycoprotein binds several different transition metal ions (2, 3), but is best characterized for its iron-binding properties and its association with host defense at mucosal surfaces (4). Perhaps more interesting are its postulated growth-promoting (5,6) and immune-modulating properties (7-1 1). The structures of human hololactofemn and apolactofemn are known (12, 13), but their full biologic significance and mechanisms of action remain the subject of continued investigations.
HEPES, N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid PAGGE, polyacrylamide gradient gel electrophoresis HFBA, heptafluorobutyric acid Lactofemn is a major constituent of human colostral milk and whey (I). This 78-kD secretory glycoprotein binds several different transition metal ions (2, 3), but is best characterized for its iron-binding properties and its association with host defense at mucosal surfaces (4) . Perhaps more interesting are its postulated growth-promoting (5,6) and immune-modulating properties (7-1 1). The structures of human hololactofemn and apolactofemn are known (12, 13) , but their full biologic significance and mechanisms of action remain the subject of continued investigations.
Utilization of lactofemn by the immature gastrointestinal system of preterm and term infants is poorly characterized. Infants fed human milk excrete higher levels of fecal lactofemn than do infants fed bovine milk-based formulas (14) (15) (16) (17) (18) . Fecal excretion, however, accounts for only a few percent (1-6%) of the lactofemn fed ( 16, 17) , and most fecal lactofemn is degraded to lower molecular mass forms (1 9-2 1). Investigators have also reported higher levels of lactofenin and lactoferrin fragments, free secretory component, and secretory IgA in the urine of infants fed human milk than in the urine of infants fed a bovine milk-based formula (21, 22) . The molecular sizes of these immune factors are larger than normally filtered by glomeruli (23) . The serum levels of lactofemn are similar in formula-and human milk-fed preterm infants (0.8 to 0.9 &mL) (22) . More recently, Scott (24, 25) has reported that the serum levels of lactofemn in preterm infants are substantially higher than in term infants, and no difference was observed between term infants fed exclusively human milk and those fed bovine milk-based formula.
To determine the origin and quantify the relative urinary concentrations of intact lactofemn and its fragments, simple and very efficient purification procedures are required. We have used immobilized DNA as an affinity method to purify human milk lactofemn (26) as well as intact lactofemn from the urine of human milk-fed preterm infants (27) . We report here the stable isotope incorporation into human milk lactofemn and its use to demonstrate the origin of intact lactofemn, and of two relatively large (5 1-and 39-kD) lactofemn fragments, present in the urine of human milk-fed preterm infants. pooled preterm infant urine. After addition of urea to 3 mol/L and pH adjustment to 7.0, the urine sample was centrifuged (1000 x g for 10 min) and the supernatant was loaded onto the ssDNA-agarose column. The column was then washed with 30 mL of 20 mmol/L HEPES buffer (pH 8.0) containing 6 mol/L urea. Urea was subsequently eliminated by washing with three bed volumes of 20 mmol/L HEPES (pH 8.0) buffer. Elution with three bed volumes each of 0.2 mol/L and 0.5 mol/L NaCl resulted in the elution of nonlactofemn proteins and lactofemn, respectively. Fractions of 2 mL were collected for determination of UV absorbance at 280 nm (Beckman model DU-70, Beckman Instruments, Fullerton, CA) and radioactivity (Packard Autogamma 5500, Packard Instrument Co., Inc., Downers Grove, IL). To regenerate the ssDNA-agarose column, it was washed with 8 mol/L guanidine hydrochloride in 20 mmol/L HEPES (pH 8.0), followed by water. The purity of the isolated lactofemn was evaluated by SDS-PAGGE and silver-staining, high-performance reverse-phase (phenyl) chromatography, high-performance ion-exchange (Mono-S) chromatography, and when possible, Nterminal amino acid sequence analyses (27, 33) .
SDS-PAGGE of purified lactoferrin. The samples from the ssDNA-agarose column were concentrated (100-to 300-fold) using a Centricon-10 (Amicon, Danvers, MA) centrifugal concentrator (10 000 molecular wt cutoff). An aliquot of the concentrated sample (50 to 100 pL) was mixed with solubilizing buffer (50 pL 2% SDS with 3% mercaptoethanol) and heated in a boiling water bath for 90 s. Electrophoresis on a 10 to 20% polyacrylamide separating gel with 4.5% stacking gel was performed essentially according to the method of Laemmli (34) . After electrophoresis, the gel was fixed with 10% acetic acid in 50% methanol, then silver stained, with minor modifications, according to the method described by Momssey (35) . Low molecular weight markers (Pharmacia LKB Biotechnology Inc., Piscataway, NJ), including phosphorylase b (94 kD), BSA (67 kD), ovalbumin (43 kD), carbonic anhydrase (30 kD), soybean trypsin inhibitor (20.1 kD), a-lactalbumin (14.4 kD), and human milk lactofemn (78 kD) standard (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA), were used to determine the molecular mass of the purified urinary lactofemn.
High-performance reverse-phase chromatography. An aliquot (50 pL) of the concentrated, purified lactofemn sample obtained from ssDNA-agarose was applied to a Vydac TP2 19 (diphenyl) Ceverse phase column (4.6 mm x 25 cm, 5-pm particle size, 300-A pore diameter; The Separations Group, Hisperia, CA) and eluted with a linear gradient of44.5 to 52.2% solvent B in solvent A over 30 min (solvent A: 0.5% HFBA in Milli-Q (Millipore Corp., Bedford, MA) water; solvent B; 0.5% HFBA in 100% acetonitrile). The flow rate was 1 mL/min and protein elution was determined by UV absorbance at 280 nm (Beckman System Gold HPLC with a model 166 or 167 UV detector, Beckman Instruments).
Electrophoretic (Western) transfer and immunoblouing. SDS-PAGGE was performed under denaturing conditions except that reducing agents were eliminated during sample preparation. Approximately 5 pg protein were loaded to each well of the gel. Western transfer (36) was performed on nitrocellulose membranes (Bio-Rad) at pH 8.3 in 0.025 M Tris, 0.19 M glycine, 20% methanol buffer at 30 V for 16 h at room temperature (22 to 25°C). After 16 h, the voltage was increased to 60 V for 1 h. The nitrocellulose membranes were blocked for 1.5 h at 37°C with 0.1 % gelatin (Bio-Rad) in 5 mM Tris-HC1, 0.15 M sodium chloride, pH 8.0. After blocking, the membrane was incubated for 1.5 h at 37°C with rabbit anti-human lactoferrin primary antibodies (purified Ig fraction) diluted in 5 mM Tris-HC1 (pH 8.0), 0.15 M NaCl, and 0.05% Tween-20. After incubation with the primary antibody, the membrane was washed three times, then incubated for 1.5 h at 37°C with diluted goat anti-rabbit IgG antibodies conjugated with horseradish peroxidase (BioRad). Color development was performed using 4-chloro-1 -naphthol with hydrogen peroxide in methanol.
Mass spectrometry. The "C, I5N, or deuterium enrichments of free leucine and lysine, respectively, were determined after ion-exchange chromatography by GC-MS (37) . Samples of pure lactofemn, isolated from mothers' milk and their infants' urine, were hydrolyzed in 500 pL of 12 N HCI for 14 h at 1 IOOC. The hydrolysates were evaporated to dryness, and converted to the n-propyl ester, N-heptafluorobutyramide derivative (38) . GC-MS analyses of these derivatives were performed in triplicate on a Hewlett Packard HP-5988A quadrupole mass spectrometer (Palo Alto, CA) using the [M-HF]-ions produced by electron-capture negative ion GC-MS (39) . Isotopic enrichment data are expressed as the molar ratio of isotopically labeled amino acid to unlabeled amino acid (x100) after correction for natural abundance as described previously (39) .
RESULTS

Incorporation of /' 'C]leucine and /I 5Nz]lysine or ['H4]lysine
into milk lactoferrin. Figure 1 shows the rate and extent of stable isotopic enrichment of maternal lactofenin purified from aliquots of the milk collected at 3-h intervals during the 48-h period of isotope infusion. All of the labeled milk collected from each subject during the 48-h period of isotope infusion was pooled and fortified with human milk powder. Enzyme-linked immunoassays indicated that these fortified pools contained 1.89 and 2.95 mg/mL lactofemn ( Table 1) Lactoferrin in the urine of human milkged preterm infants. Urine samples (8-h pools) collected from the two infants contained from 0 to 243 pg of lactofemn per mL (Table 2) . Because the urines were diluted to varying degrees during the collection process, these values do not reflect actual urine concentrations. Fig. 2 . Isolation of intact lactofemn and DNA-binding lactoferrin fragments found in the urine of preterm infants fed human milk by affinity chromatography on ssDNA-agarose as described in Materials and Methods.
The total urinary outputs of lactofemn, however, are provided in Table 2 .
Purijication and characterization of the urinary lacloferrin.
The profile shown in Figure 2 illustrates the efficiency of ssDNA affinity columns for the one-step purification of intact lactofemn and two major lactofemn fragments from the urine of human milk-fed preterm infants. The majority of urinary protein detected by absorbance at 280 nm was eluted unretained in the flow-through fractions. The elution position of the absorbed urinary lactofemn was typically not detectable by its absorbance at 280 nm alone. Thus, in separate experiments, the elution position and recovery of urinary lactofemn were verified by the addition of trace quantities (<5 pg) of [1251]-labeled lactofemn to test aliquots of preterm infant urines. Under the conditions specified, the recovery of lactofemn was routinely ( n = 50) greater than 90% and often near 100%.
SDS-PAGGE of the urinary lactofemn purified by ssDNAagarose affinity chromatography revealed the presence of proteins of 78, 5 1, and 39 kD when the gel was silver-stained (Fig.  3) . The presence of intact lactofemn (78 kD) was confirmed using polyclonal antisera to immunoblot the electrophoretic gels. Lower molecular weight lactofemn fragments were also detectable. Using the more sensitive (detection limit 50 to 100 pg) lactoperoxidase and gold conjugate immunoblot detection systems as described previously (30, 40) , these lower molecular mass (39-and 5 1-kD) proteins were also identified as immunoreactive lactofemn. To determine their possible separate metabolic origins, the intact lactofemn and its two DNA-binding fragments required separation before mass spectral analysis.
Separation of urinary lacloferrin fragments from intact lacloferrin.
The efficient micropreparative separation of the intact urinary lactofemn from the 51-and 39-kD urinary lactofemn fragments was achieved only by means of high-performance reverse-phase chromatography on phenyl-derivatized silica columns employing HFBA as the ion-pairing reagent. The profile shown in Figure 4 illustrates the elution pattern of urinary lactoferrin and lactoferrin fragments from one of the two infants fed labeled milk (the other preterm infant evaluated in this study produced urines that contained insufficient quantities of lactofemn to justify further separation of fragments by this method). SDS-PAGGE and immunoblot analyses with anti-lactofemn nntibodies were used to confirm the identity of the three reverse- 5 . Molecular mass evaluations and identification of intact urinary lactofemn and the DNA-binding lactofemn fragments isolated by affinity chromatography on ssDNA-agarose and resolved by high-performance reverse-phase chromatography. SDS-PAGGE of the afinity purified lactoferrin and lactofemn fragments was performed after resolution of these lactoferrins by high-performance reverse-phase chromatography as described in Figure 4 . Lane I shows the migration pattern of the calibrator proteins used for estimation of molecular weight. Lane 2 shows the electrophoretic migration properties of human milk lactofemn obtained from Jackson Immunoresearch Laboratories. Lane 3 illustrates the 39-kD lactofemn fragment present in peak I of the highperformance reverse-phase chromatographic elution profile shown in Figure 4 . Lane 4 shows the electrophoretic migration profile of the 5 1-kD lactoferrin fragment present in peak 2 of the high-performance reverse-phase chromatogram (Fig. 4) . Lane 5 shows the electrophoretic migration profile of the intact lactoferrin present in peak 3 of the highperformance reverse-phase chromatogram (Fig. 4) . phase peaks. The SDS-PAGGE pattern in Figure 5 shows the intact lactofemn as well as the two major DNA-binding fragments after their collective isolation by afinity chromatography on ssDNA-agarose and separation by high-performance reversephase chromatography. Immunoblot analyses confirmed the immunoreactivity of these proteins and led to the identification of the three reverse-phase peaks as the 39-kD lactofemn fragment, the 51-kD lactofemn fragment, and intact lactofemn, respectively. The isolated urinary lactofemn (and fragments) recovered from each of the 12 8-h urine pools were evaluated by GC-MS for isotopic enrichment.
Isotopic enrichment of urinary lactoferrin and its fragments.
The profiles shown in Figure 6 demonstrate the rate and extent to which isotopically labeled lactofemn appeared in the urine collected from each of the two preterm infants fed the labeled, fortified human milk. In the case of subject 2 ( Fig. 6A and B) , separate data are shown for the intact lactoferrin and the 39-and 5 1-kD lactofemn fragments isolated by reverse-phase chromatography. The horizontal line across the top of each profile indicates the isotopic enrichment of the lactofemn present in the labeled, fortified milk that was fed to each of the two infants. The rate and extent of isotopic enrichment of the intact urinary lactofemn (78 kD), the 39-kD urinary lactofemn fragment, and the 51-kD urinary lactofemn fragment were quite similar. In each case, the isotopic enrichment of ["Clleucine ( added as the free amino acid to the pooled, fortified milks from subjects 1 and 2, respectively, were not incorporated into the isolated urinary lactofemn. enrichment ofthe labeled lactofemn in the fed milk; we observed comparable (87%) degrees of isotopic enrichment in the intact urinary lactofemn isolated from the urine of infant 1 (Fig. 6 C  and D) . The maternal origin of the urinary lactofemns from each preterm infant was established by comparison of the ratios of isotopically labeled leucine to lysine in the isolated milk and urinary lactofemns. The ratio of [13C]leucine to [I5N2]lysine in the purified milk lactofenin isolated from subject 2 (1.957) was similar to that in the purified urinary lactofemn from her preterm infant (1.866). The ratio of ["C]leucine to [2H4]lysine in the purified milk lactofemn isolated from subject 1 (0.756) was essentially the same as the ratio of these amino acids found in the purified urinary lactofemn from her infant (0.743). The possible endogenous synthesis of lactofemn by the infant and, in particular, its appearance in the urine, was addressed by the addition of [1SN2]lysine (subject 1) or [2H4]lysine (subject 2) as the free amino acid to the pooled, fortified milks immediately before feeding. Neither ['SN2]lysine (subject l), nor [2H4]lysine (subject 2) was detected in the purified urinary lactofemns from either preterm infant (Fig. 6) .
Relationship of urinary lactoferrin to total urinary protein. The concentrations of total urinary protein collected over the 96-h period were similar for the two human milk-fed preterm infants studied during this investigation (Table 2 ). In contrast, however, Urinary Protein (mg/ml) Fig. 7 . Relationship between urinary lactoferrin concentrations and total urinary protein concentrations. Lactofemn concentrations in the diluted urines were determined using enzyme-linked immunosorbent sandwich assays as described in Materials and Methods.
the quantities (total output) of urinary lactofemn measured in these infants were quite different and varied significantly over the 96-h collection period ( Table 2 ). The urinary lactofemn concentrations were not related to total urinary protein concentrations (Fig. 7) . Urinary lactofemn and protein in the collected urine pools are given as concentrations in Figure 7 ; these concentrations reflect varying degrees of dilution associated with the routine urine collection procedures (29) . The data presented in Table 2 for total urinary lactofemn and protein outputs indicate that the lack of correlation between lactofemn and protein was independent of the collection procedure (i.e. dilution).
DISCUSSION
Serum levels of lactofenin in both preterm and term infants reportedly do not vary with diet (i.e. human milk versus bovine milk-based formula) (22, 24) . As a result, the origin of biologically significant quantities of lactofemn in the urine of preterm infants fed human milk has been the subject of much discussion (e.g. 2 1, 22). Because fecal excretion of lactofemn accounts for only 1 to 6% (1 5-1 7) of the dietary lactofemn in preterm infants, it has been suggested that much of the remaining lactofemn is digested (1 4-18 ). This assumption remains untested. We have now demonstrated that nearly all of the intact lactofemn in the urine of premature infants fed human milk is of maternal origin.
The similar ratios of labeled amino acids in the 78-kD lactofemn purified from milk and preterm infant urine indicated that the labeled, intact lactofemn excreted in urine by these infants was definitely of maternal origin; furthermore, the absolute levels of enrichment of [13C]leucine and [15N2]lysine or [2H4]lysine in the urinary lactofemn demonstrated that most (87 to 100%) of the recovered lactofemn was of maternal origin. This conclusion is supported by our observation that the isotopically labeled free amino acid [2H4]lysine or ['SN2]lysine (added directly to the expressed, pooled milk samples) was not incorporated into either the intact urinary lactofemn or its isolated fragments. Therefore, if endogenous lactofemn was produced, it did not appear in their urine.
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The physiologic mechanisms that account for the uptake of intact lactofemn by the gastrointestinal tract and its subsequent renal excretion were not addressed by these studies. The delay (>24 h) between the introduction of labeled lactofemn and its appearance in urine was significant. The lack of a detectable association between urinary lactofemn and total protein (either concentrations or total output) noted in the present study, and the significant correlations between the amounts of urinary immunologic factors excreted by preterm infants observed in previous studies (20) suggest that specific mechanisms are responsible for the presence of these proteins in urine. The question of selective protein excretion by infants who are fed human milk requires further analyses.
The urinary lactofemn fragments are of considerable interest. These fragments, observed in at least eight different urine pools, were separated only under denaturing conditions in vitro. under nondenaturing conditions, neither the 39-nor 5 1-kD fragments were detected. The origin, nature, and regulation of the lactoferrin cleavage event(s) are not known. The indicated fragments were not detected in the milk of these mothers, in the milk of 10 other mothers that we studied (unpublished observations), or of others studied previously (21) . These lactofemn fragments that bind to DNA also are not detected in the milk of other mammals (bovine and porcine) we have studied (unpublished observations). It is therefore likely that these fragments arise from a limited or specific proteolysis either in the gastrointestinal tract, in the systemic circulation, and/or during filtration and excretion in the urine. Preliminary N-terminal sequence analysis of the purified 39-and 5 1-kD fragments suggests that they represent portions of the N-lobe and the intact C-lobe of lactofemn, respectively. The appearance of these two lactofemn fragments only under denaturing conditions and always in a near 1: 1 stoichiometry suggests that they are not totally separated in vivo, but complexed in a manner that sustains their association (41) . The preserved DNA-binding properties of the intact lactofemn and lactofemn fragments imply that the DNA-binding domain 3f the lactofemn molecule is relatively resistant to further proteolytic degradation.
The physiologic significance to preterm infants of absorbed, ~ndegraded lactofemn remains to be established. Its uptake may xoceed by nonspecific macromolecular absorption (42) or by Nay of association with specific lactofemn receptors (43) (44) (45) (46) (47) (48) (49) . Bennett and coworkers (7) (8) (9) have shown that the DNA-binding 'unctions of lactofemn affect intercellular communications imong circulating lymphocytes, neutrophils, and granulocytes. ilthough the tertiary structure and function of the urinary actofemn has not yet been documented, the ability of lactofemn o be absorbed in its intact form suggests that it may act in a .egulatory capacity to influence the infant's developing immune rystem. The abilities of two relatively large (39-and 51-kD) DNA-binding fragments to resist further degradation and to enter he circulatory system otherwise intact suggest that they also may ~c t in a regulatory capacity. These findings suggest that at least n preterm infants who are fed human milk, lactofemn may play ! broader biologic role than has been previously appreciated. ndeed, human milk lactofemn does not appear to be a transient mmunoprotective protein localized to the gastrointestinal tract.
-he precise developmental period that may ultimately preclude he absorption and (or) renal excretion of intact lactofemn (e.g. :rm infants) is currently under investigation.
